Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Reasons why not all Danish patients with muscle invasive bladder cancer receive neoadjuvant chemotherapy before radical cystectomy

Research output: Contribution to journalJournal articleResearchpeer-review

  1. DaPeCa-4: outcome in penile cancer patients with N3 disease due to extra nodal extension treated with surgery and chemo-irradiation

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Oncological outcomes of radical nephroureterectomy for upper urinary tract urothelial neoplasia in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Educational level and first-time PSA testing in general practice

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Left sided flank pain due to Bochdalek hernia with intrathoracic kidney

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. The prognostic impact of incidental prostate cancer following radical cystoprostatectomy: a nationwide analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Oncological outcomes of radical nephroureterectomy for upper urinary tract urothelial neoplasia in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Human papillomavirus and squamous cell carcinoma of the urinary bladder: DaBlaCa-10 study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Feasibility of a fast-track cystectomy program

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Ninna Nielsen
  • Gitte Wrist Lam
  • Knud Fabrin
  • Per Holt
  • Peter Ole Thind
  • Jørgen Bjerggaard Jensen
View graph of relations

Background: Danish guidelines on muscle invasive bladder cancer (MIBC) recommend neoadjuvant chemotherapy (NAC) for non-metastatic patients fit for cisplatin-based chemotherapy. The current indication is urothelial MIBC in patients less than 75 years old with no metastasis on imaging and normal renal function (GFR ≥ 60 ml/min). Data from the Danish Bladder Cancer Database (DaBlaCa-Data) reveals that only 40-50% of MIBC patients below 75 years of age receive NAC prior to cystectomy. The aim of this study was to clarify the reasons why the remaining patients do not receive NAC. Methods: Individual patient data were collected retrospectively from all five Danish urologic departments performing cystectomies. Patients fulfilling the inclusion criteria: MIBC at TURBT, age less than 75 years old and subsequent cystectomy were included and registered by the specific reason why NAC was not given. In total, 449 patients met the age- and T-stage criteria for NAC in the period September 2014 through August 2017. Results: In total, 274 patients (61.0%) received chemotherapy. Of the 175 patients who did not receive NAC, 140 patients (80%) were not fit for cisplatin and 35 patients did not receive NAC and had no specific contraindication. This ranged from 0-18% of included patients in the different centres. The main reason was patient refusal (97%). Interestingly, this ranged from 0-50% of patients not receiving NAC when comparing the five centres. Conclusion: These findings underline the need for proper patient information in order to get a uniform treatment strategy between centres.

Original languageEnglish
JournalScandinavian Journal of Urology
Volume53
Issue number4
Pages (from-to)213-216
ISSN2168-1805
DOIs
Publication statusPublished - 2019

    Research areas

  • adherence, Bladder cancer, chemotherapy, contraindications, cystectomy, guidelines, muscle invasive, neoadjuvant

ID: 58148046